Jacobs Levy Equity Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Jacobs Levy Equity Management’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-13,233	Closed	-$299K	–	1080
2018 Q4	$299K	Buy	13,233 +5,148	+64%	+$201K	0.01%	812
2018 Q3	$446K	Buy	8,085 +1,510	+23%	+$96.4K	0.01%	801
2018 Q2	$469K	Sell	6,575 -795	-11%	-$56.1K	0.01%	811
2018 Q1	$453K	Buy	7,370 +310	+4%	+$27.2K	0.01%	792
2017 Q4	$890K	Buy	7,060 +1,670	+31%	+$214K	0.02%	638
2017 Q3	$737K	Buy	5,390 +105	+2%	+$14K	0.01%	644
2017 Q2	$754K	Sell	5,285 -365	-6%	-$56.4K	0.02%	615
2017 Q1	$1.04M	Buy	+5,650	New	+$633K	0.02%	549

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's TTPH Position: Q1 2019 in Review

Jacobs Levy Equity Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2019, closing a stake of 13,233 shares — an estimated $299K sold.

Jacobs Levy Equity Management first reported a position in TTPH in Q1 2017 and held it in 8 quarters. The position peaked at $1.04M in Q1 2017. 78 funds tracked by Wall St. Rank hold TTPH as of Q1 2019.

Jacobs Levy Equity Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Jacobs Levy Equity Management sold 13,233 Tetraphase Pharmaceuticals, Inc. shares in Q1 2019, an estimated $299K.
Jacobs Levy Equity Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2017 and held it in 8 quarters.
Jacobs Levy Equity Management's Tetraphase Pharmaceuticals, Inc. position peaked at $1.04M in Q1 2017.
78 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2019, filed 14 May 2019.